Beth C. Seidenberg Sells 1,177 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at approximately $6,737,395.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Vera Therapeutics Stock Up 1.9 %

VERA stock opened at $42.78 on Friday. The stock has a market capitalization of $2.34 billion, a PE ratio of -20.87 and a beta of 0.99. Vera Therapeutics, Inc. has a 52 week low of $9.24 and a 52 week high of $50.78. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $37.47 and a 200 day moving average of $39.09.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

VERA has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research report on Monday, September 16th. JPMorgan Chase & Co. increased their target price on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Finally, Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $51.75.

Institutional Trading of Vera Therapeutics

Large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. boosted its holdings in shares of Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after acquiring an additional 688 shares during the last quarter. Arizona State Retirement System boosted its holdings in Vera Therapeutics by 14.4% in the second quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock valued at $358,000 after purchasing an additional 1,250 shares during the last quarter. Ensign Peak Advisors Inc grew its position in Vera Therapeutics by 13.5% during the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock worth $425,000 after purchasing an additional 1,400 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Vera Therapeutics by 30.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after buying an additional 1,737 shares during the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Vera Therapeutics by 17.6% in the 1st quarter. American International Group Inc. now owns 19,764 shares of the company’s stock valued at $852,000 after buying an additional 2,957 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.